Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.

about

Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.

Item

http://www.wikidata.org/entity/Q47238436

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Comparison of conditioning reg ...... dose melphalan and bortezomib.

@en

Comparison of conditioning reg ...... dose melphalan and bortezomib.

@nl

type

Item

label

Comparison of conditioning reg ...... dose melphalan and bortezomib.

@en

Comparison of conditioning reg ...... dose melphalan and bortezomib.

@nl

prefLabel

Comparison of conditioning reg ...... dose melphalan and bortezomib.

@en

Comparison of conditioning reg ...... dose melphalan and bortezomib.

@nl

P1476

Comparison of conditioning reg ...... dose melphalan and bortezomib.

@en

P2093

Eda Aypar

http://www.w3.org/2001/XMLSchema#string

Fikret Vehbi İzzettin

http://www.w3.org/2001/XMLSchema#string

Gülsan Türköz Sucak

http://www.w3.org/2001/XMLSchema#string

Mesut Sancar

http://www.w3.org/2001/XMLSchema#string

Zeynep Arzu Yeğin

http://www.w3.org/2001/XMLSchema#string

Şahika Zeynep Akı

http://www.w3.org/2001/XMLSchema#string

P2860

Early-Onset Severe Diffuse Alveolar Hemorrhage after Bortezomib Administration Suggestive of Pulmonary Involvement of Myeloma Cells

Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.

Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma

Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma.

P304

1078155217697486

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155217697486

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29284356

http://www.w3.org/2001/XMLSchema#string